Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $90

Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $80 to $90.
byBenzinga Newsdesk
September 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $80 to $90.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts